Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
Organisation › Details
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects. Ganymed's lead program, IMAB362, is in advanced phase II testing for gastroesophageal cancer. IMAB362 binds to the tight junction protein Claudin-18.2 which is expressed in up to 80% gastroesophageal adenocarcinomas, 60% pancreatic tumors as well as in other various solid tumors. Ganymed is also developing IMAB027, a monoclonal antibody targeting GT512 which is absent in healthy adult organs, but is expressed in a wide range of solid cancers, including testicular, ovarian, uterine, and lung cancers. The company plans to initiate clinical studies with IMAB027 in the near future. Ganymed is a private company that was founded in 2001 as a spin-off from the Universities of Mainz and Zurich. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. Other investors include Future Capital AG, MIG Fonds, First Capital Partner GmbH, and private individuals. *
![]() |
Start | 2001-01-01 established |
Group | Astellas (Group) | |
![]() |
Industry | BIOTECH |
Industry 2 | claudiximab (iMAB362/GC182) | |
![]() |
Person | Türeci, Özlem (Ganymed 200811 CEO + CSO) |
Person 2 | St-Onge, Luc (Apceth Biopharma 201708 before Ganymed + Affectis CBO + DeveloGen) | |
![]() |
Region | Mainz |
Country | Germany | |
Street | 12 Freiligrathstr. | |
City | 55131 Mainz | |
Tel | +49-6131-1440-100 | |
Address record changed: 2018-07-24 | ||
Basic data | Employees | C: 51 to 100 (2016-10-28) |
* Document for �About Section�: Ganymed Pharmaceuticals AG. (9/11/13). "Press Release: Ganymed Pharmaceuticals Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors". Mechelen. | ||
Record changed: 2019-06-09 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Astellas (Group)
- [1] Audentes Therapeutics, Inc.. (12/2/19). "Press Release: Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics". Tokyo & San Francisco, CA....
- [2] Astellas Pharma Inc.. (11/22/18). "Press Release: Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas". Tokyo & Cleveland, OH....
- [3] Astellas Pharma Inc.. (8/10/18). "Press Release: Astellas Announces Acquisition of Quethera". Tokyo & Cambridge....
- [4] Eurofins Scientific. (5/22/18). "Press Release: Eurofins Expands Its Biopharmaceutical Products Testing Footprint with an Outsourcing Agreement with Astellas in Japan"....
- [5] Gilead Sciences, Inc.. (5/15/18). "Press Release: Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline". Santa Monica, CA....
- [6] Cell and Gene Therapy Catapult, The. (10/5/17). "Press Release: iPSC Line Licensed to Universal Cells to Assist in the Development of Universal Donor Cell line"....
- [7] Vesalius Biocapital Partners Sàrl. (5/18/17). "Press Release: Vesalius Biocapital Announces First Close of Its Third Fund". Bertrange....
- [8] Ogeda S.A.. (5/17/17). "Press Release: Astellas Completes Acquisition of Ogeda SA". Tokyo....
- [9] Ogeda S.A.. (4/3/17). "Press Release: Astellas to Acquire Ogeda SA". Tokyo & Gosselies....
- [10] Freshfields Bruckhaus Deringer. (10/28/16). "Pressemitteilung: Krebstherapie – Freshfields berät Ganymed-Eigner beim Verkauf an Astellas Pharma"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top